Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] SK Square (402340) – Decision on Issuance of Depositary Receipts / 2026-06-24 Semiconductors
  • [Disclosure] Samsung Biologics (207940) – Decision on Corporate Spin-off / 2025-05-22 Disclosures
  • [Disclosure] HPSP (403870) – Execution of Stock Pledge Agreement Involving Change of Largest Shareholder / 2025-05-16 Semiconductors
  • [Disclosure] SK Hynix (000660 / SKHY) – New Facility Investment / 2024-04-24 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Results of Issuance of New Shares or Equity-Related Bonds / 2025-07-09 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Decision on Provision of Debt Guarantee for Others / 2026-02-13 Disclosures
  • [Disclosure] Hana Micron (067310) – Investor Relations (IR) Holding / 2025-07-07 Semiconductors
  • [Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the US / 2026-03-12 Disclosures

[Disclosure] SK Hynix (000660 / SKHY) – Results of Capital Increase or Issuance of Equity-Related Bonds (Voluntary Disclosure) / 2026-07-15

Posted on July 15, 2026August 11, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART
Market: KOSPI (000660)

💡 3-Second Summary

SK Hynix disclosed the results of its third-party capital increase for issuing American Depositary Receipts (ADRs) overseas, with the actual issue amount finalized at KRW 39.89T.

📊 [Key Summary & Financial Figures]

  • Company Name: SK Hynix Inc.
  • Stock Code: 000660
  • Security Type: Registered Common Shares
  • Issuance Method: Third-Party Capital Increase
  • Expected / Actual Issued Shares: 17,790,000 shares / 17,790,000 shares
  • Expected Issue Amount: KRW 40,023,070,290,000 (approx. KRW 40.02T)
  • Actual Issue Amount: KRW 39,890,534,790,000 (approx. KRW 39.89T)
  • Initial Board Resolution Date: June 24, 2026
  • Payment Date: July 14, 2026
  • Other Key Decision Details:
    • All new shares are issued to overseas depositary Citibank, N.A. via third-party allocation, based on which American Depositary Receipts (ADRs) will be issued to overseas institutional investors.
    • Expected issue amount calculated using $26.5071B ADR total offering applied with USD/KRW rate of 1,509.90 (as of Pricing Date, July 9, 2026).
    • Actual issue amount calculated using $26.5071B ADR total offering applied with USD/KRW rate of 1,504.90 (as of Payment Date, July 14, 2026).

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verifying Differences Between Provisional Figures and Final Confirmed Figures

This disclosure presents the actual issue amount and final issuance results applied with the exchange rate as of the payment date for the overseas ADR offering. Checking the difference between the initially expected amount and the actual finalized amount is important to understand changes between provisional and final figures. Detailed issuance results can be verified through subsequent periodic reports (Quarterly, Half-Year, or Annual Reports).

📌 Checking Share Count Changes and Subsequent Disclosures

As the results of issuing 17,790,000 common shares through third-party allocation are finalized, they will be reflected in the company’s total issued shares. Verifying the actual number of shares issued and the resulting share structure is important to understand changes in total remaining shares and capital stock. Relevant details can be confirmed in subsequent periodic reports (Quarterly, Half-Year, or Annual Reports) and additional listing disclosures.

📢 Disclaimer and Source Notice

Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s DART system.

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Execution of Sales / Supply Contract / 2026-07-15
Next Post: [Disclosure] SK Hynix (000660 / SKHY) – Investor Relations (IR) Hosting (Notice Disclosure) / 2026-07-15

Related Posts

  • [Disclosure] KEPCO (015760 / KEP) – Investor Relations (IR) Holding Announcement / 2025-11-10 Disclosures
  • [Disclosure] ISU PETASYS (007660) – Decision on Cash and In-Kind Dividend / 2024-02-20 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Execution of Sales / Supply Contract / 2026-03-31 Disclosures
  • [Disclosure] SK Square (402340) – Modification of Listing / 2025-04-23 Semiconductors
  • [Disclosure] Hanwha Systems (272210) – Submission of Audit Report / 2025-03-13 Disclosures
  • [Disclosure] SK Square (402340) – Information on Reference Price for Interim (Quarterly) Ex-Dividend / 2026-05-13 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – Other Information / 2024-06-19 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Investment Certificates of Other Corporations / 2026-07-08 Disclosures
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Server DDR5 · eSSD · Supply-Demand Tightness / 2025-10-30 RESEARCH
  • [Disclosure] SK Square (402340) – Change of Listing / 2025-01-16 Semiconductors
  • [Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Holding / 2025-05-16 Semiconductors
  • [Disclosure] SK square (402340) – Losses Incurred from Derivatives Transactions / 2026-02-25 Semiconductors
  • [Disclosure] HPSP (403870) – Results of Extraordinary General Meeting of Shareholders / 2025-11-07 Semiconductors
  • [Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in Europe (Part 1 & 2) / 2024-10-14 Bio & Healthcare

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme